---

name: report-generator description: | Generate professional drug discovery reports including target dossiers, competitive briefs, and Go/No-Go decision summaries.

Use this skill when you need formatted reports for presentations, decision meetings, or documentation. Supports multiple output formats.

Keywords: report, dossier, decision, go-no-go, brief, presentation category: Report Generation tags: [report, dossier, decision, go-no-go] version: 1.0.0 author: Drug Discovery Team dependencies: []

Report Generator Skill

Generate professional drug discovery intelligence reports.

Quick Start

Copy/dossier EGFR --format pdf
/brief EGFR competitors --format ppt
/gng project-KRAS --full
/report --template competitor-brief
Generate a Go/No-Go report for HER2 inhibitor project

What's Included

Report Types

1. Target Dossier (/dossier)

Comprehensive target analysis for validation decisions.

Sections:

• Executive Summary (1 page)
• Target Overview
• Druggability Assessment
• Disease Associations
• Competitive Landscape
• Safety Assessment
• Opportunities & Risks
• Recommendations

Output: PDF (10-15 pages)

Copy/dossier EGFR
/target-dossier KRAS G12C --format pdf
Generate dossier for BRAF V600E

2. Competitor Brief (/brief)

Competitive intelligence summary for portfolio reviews.

Sections:

• Market Overview
• Approved Products
• Pipeline Analysis
• Company Landscape
• Key Differentiators
• White Space

Output: PPT (8-12 slides)

Copy/brief EGFR inhibitors
/competitor-brief GLP-1 agonists --format ppt
Create competitor brief for obesity market

3. Go/No-Go Analysis (/gng)

Decision support with multi-dimensional scoring.

Scoring Dimensions:

Score Interpretation:

• 80-100: Strong Go - Proceed with confidence
• 60-79: Go with conditions - Address specific concerns
• 40-59: Caution - Significant concerns, re-evaluate
• 0-39: No-Go - Do not proceed

Output: PDF with scorecard (5-8 pages)

Copy/gng project-EGFR-4thgen
/go-no-go KRAS inhibitor --full
Generate Go/No-Go analysis for ADC program

4. Weekly Update (/weekly)

Weekly intelligence summary for team alignment.

Sections:

• Key Developments
• Literature Highlights
• Pipeline Updates
• Conference Abstracts
• Deals & News

Output: Email/Markdown (1-2 pages)

Copy/weekly --targets EGFR,KRAS,HER2
/weekly-update --diseases NSCLC,CRC
Generate weekly report for oncology portfolio

5. Project Overview (/report --full)

Complete analysis combining all above sections.

Output: Full report (30-50 pages)

Copy/report --full EGFR program
/generate full project report for KRAS G12C

Output Formats

Go/No-Go Scoring Example

Copy# Go/No-Go Analysis: KRAS G12C Inhibitor Project

## Overall Score: 72/100 (Go with Conditions)

### Dimension Scores

| Dimension | Score | Weight | Weighted | Status |
|-----------|-------|--------|----------|--------|
| Scientific Rationale | 85/100 | 25% | 21.25 | ✅ Strong |
| Differentiation | 65/100 | 20% | 13.00 | ⚠️ Moderate |
| Feasibility | 75/100 | 20% | 15.00 | ✅ Good |
| Commercial | 80/100 | 20% | 16.00 | ✅ Strong |
| IP/Safety | 50/100 | 15% | 7.50 | ⚠️ Concern |

### Detailed Assessment

#### Scientific Rationale (85/100) ✅
**Strengths:**
- KRAS G12C validated in NSCLC, CRC
- Strong genetic association
- Clear mechanism of action

**Score:** 85/100

#### Differentiation (65/100) ⚠️
**Strengths:**
- First-in-class opportunity
- Novel covalent binding

**Concerns:**
- 4 competitors in Phase II/III
- Amgen and Mirati ahead

**Score:** 65/100

#### Feasibility (75/100) ✅
**Strengths:**
- Proven chemistry platform
- Clear PK/PD biomarkers

**Concerns:**
- Resistance mutations observed
- Combination complexity

**Score:** 75/100

#### Commercial (80/100) ✅
**Strengths:**
- Large NSCLC market
- Premium pricing potential
- Expansion to CRC, pancreatic

**Score:** 80/100

#### IP/Safety (50/100) ⚠️
**Concerns:**
- Patent landscape crowded
- Off-target toxicity risks
- Sotorasib safety signals

**Score:** 50/100

### Conditions to Proceed

1. **IP:** Conduct FTO analysis, explore novel binding pocket
2. **Safety:** Early toxicity profiling, off-target screening
3. **Differentiation:** Focus on combination strategies, CNS penetration

### Recommendation
**PROCEED with Conditions** - Strong scientific and commercial rationale,
but address IP position and safety profile before major investment.

Examples

Target Dossier

Copy/dossier EGFR
Generate a target dossier for HER2
/target-dossier KRAS --focus safety

Competitor Brief

Copy/brief EGFR TKIs
Create competitor brief for obesity drugs
/competitor-brief GLP-1 --format ppt --include-privates

Go/No-Go

Copy/gng my-project-name
/go-no-go KRAS G12C --full
Generate decision report for ADC platform

Weekly Update

Copy/weekly
/weekly-update --targets EGFR,KRAS --format email

Custom Report

Copy/report --template custom --sections exec-sum,market,competition
/generate report using template project-overview

Running Scripts

Copy# Generate dossier
python scripts/generate_dossier.py EGFR --format pdf --output reports/

# Generate brief
python scripts/generate_brief.py "EGFR inhibitors" --format ppt

# Go/No-Go with custom weights
python scripts/generate_gng.py project-name --weights science=30,diff=15

# Weekly report
python scripts/weekly_report.py --targets EGFR,KRAS,HER2 --format email

Requirements

For PDF/PPT generation:

Copypip install weasyprint python-pptx jinja2 pandas

Additional Resources

• Template Reference
• Customization Guide
• Script Usage

Best Practices

1. Specify format: Always include output format
2. Use templates: Reference existing templates for consistency
3. Include context: Add project-specific considerations
4. Review scores: Validate Go/No-Go assumptions
5. Version control: Track report iterations

Report Templates

Templates are in templates/ directory:

Copytemplates/
├── target-dossier.md      # Target validation report
├── competitor-brief.md    # Competitive intelligence
├── go-no-go.md            # Decision support
├── weekly-update.md       # Weekly intelligence
└── project-overview.md    # Full project analysis

Common Pitfalls